Gram-positive Bacterial Infections Market

Gram-positive Bacterial Infections Market (Drug Type - Antibiotic (B-Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols), Antifungal; Disease - MRSA, Pneumonia, Sepsis, Sinusitis, Cellulitis, Otitis, Pharyngitis, Impetigo; Route of Administration - Enteral, Parenteral; Distribution Channel - Hospital Pharmacies, Drug Stores and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Gram-positive Bacterial Infections Market: Snapshot

The global gram-positive bacterial infections market is expected to demonstrate upward curve of growth during the forecast period of 2018 to 2026. Some of the key reasons for this growth are significant growth in patients living with gram-positive bacterial infections and a swift increase in antibacterial resistance. Gram-positive bacterial infection drugs are effective option in the treatment of various infections including sinusitis, MRSA infections, and pneumonia.

Gram-positive bacteria are considered as a key class of bacteria responsible for causing numerous infections in humans. They are known for retaining gram stain. Under microscope, they are observed as violet purple colored stains. Gram-positive bacterial infection drugs use diverse mechanisms including protein biosynthesis inhibition, cell wall synthesis inhibition, and DNA replication inhibition.

Vendors working in the global gram-positive bacterial infections market are heavily investing in research activities. This move is helping them to offer superior quality drugs. As a result, the market for gram-positive bacterial infections is witnessing stupendous expansion avenues in the upcoming period. Apart from this, government bodies of many countries across the world are taking initiatives to support in finding out advanced bacterial infection treatment. For this purpose, they are backing various research and development activities. This is working as a driver for the global gram-positive bacterial infections market.

Several enterprises from the global gram-positive bacterial infections market are executing various strategies such as collaborations and partnerships. Key motive behind these moves is regional expansion. In addition to this, increased number of mergers and acquisitions connotes that the global gram-positive bacterial infections market will grow at rapid pace during upcoming years.

The gram-positive bacterial infections market is expected to experience significant growth avenues in North America. Remarkable increase in the number of people living with bacterial infections, presence of key players, and improved diagnosis and treatment rate are some of the key reasons fueling the market growth in the region.

Gram-positive Bacterial Infections Market – Snapshot

Gram-positive bacterial infection drugs act against gram-positive bacterial infections such as MRSA infections, sinusitis, and pneumonia. Gram-positive bacteria are those class of bacteria that retain gram stain and hence, are observed as violet purple colored stains when observed under the microscope. They are a major class of bacteria that cause various infections in humans. These drugs act by various mechanisms such as inhibition of cell wall synthesis, inhibition of protein biosynthesis, and inhibition of DNA replication. The global gram-positive bacterial infections market was valued at around US $ 51,450 Mn in 2017. It is expected to expand at a CAGR of 1.5% from 2018 to 2026. The market for gram-positive bacterial infections is expanding significantly, owing to an increase in the number of cases of gram-positive bacterial infections and a rapid rise in antibacterial resistance. Increased government initiatives and funding for R&D activities & newer bacterial infection treatment and infection control in healthcare settings is also a key factors driving the market globally.

gram-positive-bacterial-infections-market.jpg

The gram-positive bacterial infections market has been segmented based on drug type, disease, route of administration, distribution channel, and region. Based on drug type, the global market is classified into antibiotic, antifungal, and others. The antibiotic segment has been further sub-segmented into B-lactam, quinolones, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, and others. The antibiotic segment dominated the global market and is expected to maintain its position during the forecast period owing to better efficacy in treatment of wide spectrum of bacterial infections and development of novel approaches for new antibiotics. The others segment, which includes antitoxins, corticosteroids, supplements, anti-dialectic, calcium, probiotics, is expected to expand at a higher CAGR during the forecast period owing to the popularity of combination drugs prescribed for patients who are more prone to the adverse effects of single antibiotic prescription. Based on disease, the global gram-positive bacterial infections market has been divided into MRSA, pneumonia, sepsis, sinusitis, cellulitis, otitis, pharyngitis, impetigo, and others. The sinusitis segment is dominant owing to the rise in prevalence of sinusitis and increased usage of antibiotics for this infection. The otitis segment is projected to expand at a higher CAGR during the forecast period due to a rise in the prevalence of otitis media and the efficacy and safety of antibacterial agents to cure the infection. In terms of route of administration, the global gram-positive bacterial infections market has been classified into enteral, parenteral and others. The enteral segment dominated the market global market. Patient preference, ease of administration and ability to achieve desired therapeutic concentration are some factors driving the enteral segment. Based on distribution channel, the global gram-positive bacterial infections market has been segregated into hospital pharmacies, drug stores and retail pharmacies, and others. The others segment, which consist of online pharmacies and mail pharmacies, is projected to expand at a notably higher CAGR. This expanded CAGR is attributed to better discounted rates on drug purchase and convenience offered by online pharmacies.

In terms of region, the global gram-positive bacterial infections market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global gram-positive bacterial infections market in 2017, owing to a rise in the prevalence of bacterial infections, better diagnosis and treatment rate, and presence of major players in the region. Asia Pacific is a lucrative market for gram-positive bacterial infections, and the market is estimated to expand at a prominent CAGR during the forecast period due to larger patient pool and rising number of infected cases in the region.

Key players operating in the global Gram-Positive Bacterial Infections market include Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithkline plc (GSK), Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc.

Newer Options for Infection Control Propels Growth in Gram-Positive Bacterial Infections Market

Manufacturers and researchers in the global gram-positive bacterial infections market are looking forward to developing newer treatment and infection control solutions. Increasing number of research studies, clinical trials, and drug discovery processes are being undertaken by industry players to meet the rising demand for cost effective and fast acting antibiotic and antibacterial drug formulations. For example, a company called ‘Basilea Pharmaceutica’ announced the positive results for the phase 3 target study of their antibiotic drug product called ‘Ceftobiprole’. This drug is designed to treat acute bacterial skin disorders and skin structure infections. Furthermore, Bayer Global launched an antibiotic natural dipeptide known as ‘TAN 1057 AB’ that shows promising antibacterial activity against the staphylococci, including staphylococcus aureus that resists methicillin.

Increased government participation in supporting the ongoing research and development activities is anticipated to act favorably for the growing gram-positive bacterial infections market. Furthermore, factors such as increasing awareness among global population regarding the severe effects of infectious diseases and rapidly increasing technological strides in antibacterial resistance are supplementing the increased demand in global gram-positive bacterial infections market. However, there are some concerning factors that can impede the market growth in coming years. These factors include high cost of treatment, ignorance and lack of awareness regarding the proper identification of symptoms, and stringent government regulations. These factors, along with high cost associated with research and development processes for designing and developing newer drug therapies can hinder the growth of global gram-positive bacterial infections market in near future. Like every other industry, the global gram-positive bacterial infections market was also deeply impacted by the global COVID-19 pandemic. As of yet, there is no drug or therapeutic product in the market that can assist in killing the COVID-19 virus. However, many research firms and pharmaceutical manufacturers are increasingly investing in initiative to develop products that can effectively eliminate novel coronavirus.

The global gram-positive bacterial infections market has been segmented as follows:

Drug Type

 

  • Antibiotic
    • B-lactam
    • Quinolones
    • Macrolides
    • Tetracyclines
    • Aminoglycosides
    • Sulfonamides
    • Phenicols
    • Others
  • Antifungal
  • Others (Antitoxins, Corticosteroids, Supplements, Anti-Dialectic)

Disease

  • MRSA
  • Pneumonia
  • Sepsis
  • Sinusitis
  • Cellulitis
  • Otitis
  • Pharyngitis
  • Impetigo
  • Others (Anthrax, Erysipelothricosis, Necrotizing Fasciitis, Scarlet Fever, and Listeria)

Route of Administration

 

  • Enteral
  • Parenteral
  • Others (Topical, Transdermal)

Distribution Channel

 

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Others (Online Pharmacies, Mail Pharmacies, and Home Care Pharmacies)

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Gram-positive Bacterial Infections Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Drug Type Definition
                4.1.2. Global Gram-positive Bacterial Infections Market Taxonomy
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Gram-positive Bacterial Infections Market Analysis and Forecast, 2016–2026
                4.4.1. Market Revenue Projections (US$ Mn)
         4.5. Porter’s Five Force Analysis

    5. Market Outlook
         5.1. Patent Landscape
         5.2. Key Success Factors of Top Players
         5.3. Branded vs. Generic Drugs Overview

    6. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Drug Type
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
                6.3.1. Antibiotic
                         6.3.1.1. B-Lactam
                         6.3.1.2. Quinolones
                         6.3.1.3. Macrolides
                         6.3.1.4. Tetracyclines
                         6.3.1.5. Aminoglycosides
                         6.3.1.6. Sulfonamides
                         6.3.1.7. Phenicols
                         6.3.1.8. Others
                6.3.2. Antifungal
                6.3.3. Others
         6.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type

    7. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Disease
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
                7.3.1. MRSA
                7.3.2. Pneumonia
                7.3.3. Sepsis
                7.3.4. Sinusitis
                7.3.5. Cellulitis
                7.3.6. Otitis
                7.3.7. Pharyngitis
                7.3.8. Impetigo
                7.3.9. Others
         7.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type

    8. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Route of Administration
         8.1. Introduction & Definition
         8.2. Key Findings / Developments
         8.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
                8.3.1. Enteral
                8.3.2. Parenteral
                8.3.3. Others
         8.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration

    9. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Distribution Channel
         9.1. Introduction & Definition
         9.2. Key Findings / Developments
         9.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
                9.3.1. Hospital Pharmacies
                9.3.2. Drug Stores and Retail Pharmacies
                9.3.3. Others
         9.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel

    10. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Region
         10.1. Key Findings
         10.2. Global Gram-positive Bacterial Infections Market Value Forecast, by Region
                10.2.1. North America
                10.2.2. Europe
                10.2.3. Asia Pacific
                10.2.4. Latin America
                10.2.5. Middle East & Africa
         10.3. Global Gram-positive Bacterial Infections Market Attractiveness, by Region

    11. North America Gram-positive Bacterial Infections Market Analysis and Forecast
         11.1. Introduction
                11.1.1. Key Findings
         11.2. North America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
                11.2.1. Antibiotic
                         11.2.1.1. B-Lactam
                         11.2.1.2. Quinolones
                         11.2.1.3. Macrolides
                         11.2.1.4. Tetracyclines
                         11.2.1.5. Aminoglycosides
                         11.2.1.6. Sulfonamides
                         11.2.1.7. Phenicols
                         11.2.1.8. Others
                11.2.2. Antifungal
                11.2.3. Others
         11.3. North America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
                11.3.1. MRSA
                11.3.2. Pneumonia
                11.3.3. Sepsis
                11.3.4. Sinusitis
                11.3.5. Cellulitis
                11.3.6. Otitis
                11.3.7. Pharyngitis
                11.3.8. Impetigo
                11.3.9. Others
         11.4. North America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
                11.4.1. Enteral
                11.4.2. Parenteral
                11.4.3. Others
         11.5. North America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
                11.5.1. Hospital Pharmacies
                11.5.2. Drug Stores and Retail Pharmacies
                11.5.3. Others
         11.6. North America Gram-positive Bacterial Infections Market Value Forecast, by Country, 2016–2026
                11.6.1. U.S.
                11.6.2. Canada
         11.7. North America Gram-positive Bacterial Infections Market Attractiveness Analysis
                11.7.1. By Drug Type
                11.7.2. By Disease
                11.7.3. By Route of Administration
                11.7.4. By Distribution Channel
                11.7.5. By Country

    12. Europe Gram-positive Bacterial Infections Market Analysis and Forecast
         12.1. Introduction
                12.1.1. Key Findings
         12.2. Europe Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
                12.2.1. Antibiotic
                         12.2.1.1. B-Lactam
                         12.2.1.2. Quinolones
                         12.2.1.3. Macrolides
                         12.2.1.4. Tetracyclines
                         12.2.1.5. Aminoglycosides
                         12.2.1.6. Sulfonamides
                         12.2.1.7. Phenicols
                         12.2.1.8. Others
                12.2.2. Antifungal
                12.2.3. Others
         12.3. Europe Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
                12.3.1. MRSA
                12.3.2. Pneumonia
                12.3.3. Sepsis
                12.3.4. Sinusitis
                12.3.5. Cellulitis
                12.3.6. Otitis
                12.3.7. Pharyngitis
                12.3.8. Impetigo
                12.3.9. Others
         12.4. Europe Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
                12.4.1. Enteral
                12.4.2. Parenteral
                12.4.3. Others
         12.5. Europe Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
                12.5.1. Hospital Pharmacies
                12.5.2. Drug Stores and Retail Pharmacies
                12.5.3. Others
         12.6. Europe Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
                12.6.1. Germany
                12.6.2. U.K.
                12.6.3. France
                12.6.4. Italy
                12.6.5. Spain
                12.6.6. Rest of Europe
         12.7. Europe Gram-positive Bacterial Infections Market Attractiveness Analysis
                12.7.1. By Drug Type
                12.7.2. By Disease
                12.7.3. By Route of Administration
                12.7.4. By Distribution Channel
                12.7.5. By Country/Sub-region

    13. Asia Pacific Gram-positive Bacterial Infections Market Analysis and Forecast
         13.1. Introduction
                13.1.1. Key Findings
         13.2. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
                13.2.1. Antibiotic
                         13.2.1.1. B-Lactam
                         13.2.1.2. Quinolones
                         13.2.1.3. Macrolides
                         13.2.1.4. Tetracyclines
                         13.2.1.5. Aminoglycosides
                         13.2.1.6. Sulfonamides
                         13.2.1.7. Phenicols
                         13.2.1.8. Others
                13.2.2. Antifungal
                13.2.3. Others
         13.3. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
                13.3.1. MRSA
                13.3.2. Pneumonia
                13.3.3. Sepsis
                13.3.4. Sinusitis
                13.3.5. Cellulitis
                13.3.6. Otitis
                13.3.7. Pharyngitis
                13.3.8. Impetigo
                13.3.9. Others
         13.4. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
                13.4.1. Enteral
                13.4.2. Parenteral
                13.4.3. Others
         13.5. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
                13.5.1. Hospital Pharmacies
                13.5.2. Drug Stores and Retail Pharmacies
                13.5.3. Others
         13.6. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
                13.6.1. China
                13.6.2. India
                13.6.3. Japan
                13.6.4. Australia & New Zealand
                13.6.5. Rest of APAC
         13.7. Asia Pacific Gram-positive Bacterial Infections Market Attractiveness Analysis
                13.7.1. By Drug Type
                13.7.2. By Disease
                13.7.3. By Route of Administration
                13.7.4. By Distribution Channel
                13.7.5. By Country/Sub-region

    14. Latin America Gram-positive Bacterial Infections Market Analysis and Forecast
         14.1. Introduction
                14.1.1. Key Findings
         14.2. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type,2016–2026
                14.2.1. Antibiotic
                         14.2.1.1. B-Lactam
                         14.2.1.2. Quinolones
                         14.2.1.3. Macrolides
                         14.2.1.4. Tetracyclines
                         14.2.1.5. Aminoglycosides
                         14.2.1.6. Sulfonamides
                         14.2.1.7. Phenicols
                         14.2.1.8. Others
                14.2.2. Antifungal
                14.2.3. Others
         14.3. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
                14.3.1. MRSA
                14.3.2. Pneumonia
                14.3.3. Sepsis
                14.3.4. Sinusitis
                14.3.5. Cellulitis
                14.3.6. Otitis
                14.3.7. Pharyngitis
                14.3.8. Impetigo
                14.3.9. Others
         14.4. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
                14.4.1. Enteral
                14.4.2. Parenteral
                14.4.3. Others
         14.5. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
                14.5.1. Hospital Pharmacies
                14.5.2. Drug Stores and Retail Pharmacies
                14.5.3. Others
         14.6. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
                14.6.1. Brazil
                14.6.2.Mexico
                14.6.3. Rest of LATAM
         14.7. Latin America Gram-positive Bacterial Infections Market Attractiveness Analysis
                14.7.1. By Drug Type
                14.7.2. By Disease
                14.7.3. By Route of Administration
                14.7.4. By Distribution Channel
                14.7.5. By Country/Sub-region

    15. Middle East & Africa Gram-positive Bacterial Infections Market Analysis and Forecast
         15.1. Introduction
                15.1.1. Key Findings
         15.2. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
                15.2.1. Antibiotic
                         15.2.1.1. B-Lactam
                         15.2.1.2. Quinolones
                         15.2.1.3. Macrolides
                         15.2.1.4. Tetracyclines
                         15.2.1.5. Aminoglycosides
                         15.2.1.6. Sulfonamides
                         15.2.1.7. Phenicols
                         15.2.1.8. Others
                15.2.2. Antifungal
                15.2.3. Others
         15.3. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
                15.3.1. MRSA
                15.3.2. Pneumonia
                15.3.3. Sepsis
                15.3.4. Sinusitis
                15.3.5. Cellulitis
                15.3.6. Otitis
                15.3.7. Pharyngitis
                15.3.8. Impetigo
                15.3.9. Others
         15.4. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
                15.4.1. Enteral
                15.4.2. Parenteral
                15.4.3. Others
         15.5. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
                15.5.1. Hospital Pharmacies
                15.5.2. Drug Stores and Retail Pharmacies
                15.5.3. Others
         15.6. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
                15.6.1. GCC Countries
                15.6.2.South Africa
                15.6.3. Rest of Middle East & Africa
         15.7. Market Attractiveness Analysis
                15.7.1. By Drug Type
                15.7.2. By Disease
                15.7.3. By Route of Administration
                15.7.4. By Distribution Channel
                15.7.5. By Country/Sub-region

    16. Competition Landscape
         16.1. Market Player-Competition Matrix(By Tier and Size of companies)
         16.2. Market Share Analysis By Tier and Size of the Company(2017)
         16.3. Company Profiles
                16.3.1. Bayer AG
                16.3.2. Pfizer, Inc.
                16.3.3. Sanofi
                16.3.4. GlaxoSmithKline plc
                16.3.5. Merck & Co., Inc.
                16.3.6. AstraZeneca
                16.3.7. Theravance Biopharma
                16.3.8. Bristol-Myers Squibb Company
                16.3.9. Novartis AG
                16.3.10. Allergan plc.

    List of Tables

    Table 01: Recent Patents, Gram-Positive Bacterial Infection Drugs
    Table 02: Branded Drug Patents and Generic Drugs Overview
    Table 03: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 04: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
    Table 05: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
    Table 06: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
    Table 07: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 08: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 09: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 10: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 11: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
    Table 12: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
    Table 13: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
    Table 14: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 15: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 16: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 17: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
    Table 18: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
    Table 19: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
    Table 20: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 21: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 22: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 23: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
    Table 24: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
    Table 25: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
    Table 26: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 27: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 28: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 29: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
    Table 30: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
    Table 31: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
    Table 32: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 33: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 34: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 35: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016–2026
    Table 36: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016–2026
    Table 37: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
    Table 38: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

    List of Figures

    Figure 01: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
    Figure 02: Revenue Share, by Drug Type
    Figure 03: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, 2016–2026
    Figure 04: Global Gram-positive Bacterial Infections Market Value Share, by Drug Type (2017)
    Figure 05: Global Gram-positive Bacterial Infections Market Value Share, by Disease (2017)
    Figure 06: Global Gram-positive Bacterial Infections Market Value Share, by Route of Administration (2017)
    Figure 07: Global Gram-positive Bacterial Infections Market Value Share, by Distribution Channel (2017)
    Figure 08: Global Gram-positive Bacterial Infections Market Value Share, by Region (2017)
    Figure 09: Number of Patent Applications, 2010-2018 (Based on Priority Year)
    Figure 10: Patent Application, by Priority Country (2010-2018)
    Figure 11: Contributions (%), from Key Applications- 2010 to 2018 
    Figure 12: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Drug Type, 2017 and 2026
    Figure 13: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Antibiotic, 2016?2026
    Figure 14: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Antifungal, 2016?2026
    Figure 15: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
    Figure 16: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Drug Type
    Figure 17: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Disease, 2017 and 2026
    Figure 18: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by MRSA, 2016–2026
    Figure 19: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Pneumonia, 2016–2026
    Figure 20: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Sepsis, 2016–2026
    Figure 21: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Sinusitis, 2016–2026
    Figure 22: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Cellulitis, 2016–2026
    Figure 23: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Otitis, 2016–2026
    Figure 24: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharyngitis, 2016–2026
    Figure 25: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Impetigo, 2016–2026
    Figure 26: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
    Figure 27: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Disease
    Figure 28: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Route of Administration, 2017 and 2026
    Figure 29: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Enteral, 2016–2026
    Figure 30: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2016–2026
    Figure 31: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
    Figure 32: Gram-positive Bacterial Infections Market Attractiveness Analysis, by Route of Administration
    Figure 33: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 34: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
    Figure 35: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Drug Stores and Retail Pharmacies, 2016–2026
    Figure 36: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
    Figure 37: Gram-positive Bacterial Infections Market Attractiveness Analysis, by Distribution Channel
    Figure 38: Global Gram-positive Bacterial Infections Market Value Share, by Region, 2017 and 2026
    Figure 39: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Region, 2018–2026
    Figure 40: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 41: North America Gram-positive Bacterial Infections Market Value Share, by Country, 2017 and 2026
    Figure 42: North America Gram-positive Bacterial Infections Market Attractiveness, by Country, 2017–2026
    Figure 43: North America Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
    Figure 44: North America Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
    Figure 45: North America Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
    Figure 46: North America Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
    Figure 47: North America Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
    Figure 48: North America Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
    Figure 49: North America Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 50: North America Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
    Figure 51: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 52: Europe Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 53: Europe Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 54: Europe Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
    Figure 55: Europe Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
    Figure 56: Europe Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
    Figure 57: Europe Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
    Figure 58: Europe Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
    Figure 59: Europe Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
    Figure 60: Europe Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 61: Europe Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
    Figure 62: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 63: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 64: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 65: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
    Figure 66: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
    Figure 67: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
    Figure 68: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
    Figure 69: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
    Figure 70: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
    Figure 71: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 72: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
    Figure 73: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 74: Latin America Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 75: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 76: Latin America Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
    Figure 77: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
    Figure 78: Latin America Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
    Figure 79: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
    Figure 80: Latin America Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
    Figure 81: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
    Figure 82: Latin America Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 83: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026
    Figure 84: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 85: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 86: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 87: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
    Figure 88: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017–2026
    Figure 89: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
    Figure 90: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017–2026
    Figure 91: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
    Figure 92: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017–2026
    Figure 93: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 94: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017–2026

Copyright © Transparency Market Research, Inc. All Rights reserved